vunacizumab

Vunacizumab (TB-402) is a recombinant human monoclonal antibody that was developed for the prevention and treatment of venous thromboembolism (VTE) and the prevention of stroke in patients with atrial fibrillation. It functions through the partial inhibition of Coagulation factor VIII (FVIII), a critical cofactor in the blood coagulation cascade. This mechanism was designed to provide a safer anticoagulant profile by reducing the risk of excessive bleeding compared to total factor inhibition. Vunacizumab is notable for its exceptionally long half-life of approximately three weeks, which supports a single-injection dosing regimen for long-term antithrombotic protection. The drug was co-developed by ThromboGenics (now Oxurion) and BioInvent International. Although it reached Phase II clinical trials for VTE prevention following major orthopedic surgeries, its development has since been discontinued.

Other names

vunacizumabAnti-Factor VIII antibody